Health Canada accepts SNDS filing and grants priority review of oral edarvarone formulation for the treatment of ALS

Mitsubishi Tanabe Pharma

13 May 2022 - Mitsubishi Tanabe Pharma Canada announced today that Health Canada has accepted the filing of a supplement to a new drug submission for an investigational oral formulation of edaravone (MT-1186) indicated for the treatment of amyotrophic lateral sclerosis. 

Health Canada has also granted a priority review, which is expected to expedite the review timelines.

Read Mitsubishi Tanabe press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , Canada , Dossier